Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting mitochondria in melanoma: Interplay between MAPK signaling pathway and mitochondrial dynamics.

Biochemical pharmacology - 1 Aug 2020

Ferraz Letícia Silva, Costa Renata Torres da, Costa Cláudia Alves da, Ribeiro César Augusto João, Arruda Denise Costa, Maria-Engler Silvya Stuchi, Rodrigues Tiago

Abstract excerpt

Melanoma is a malignant proliferative disease originated in melanocytes, characterized by high metastatic activity and by the activation of oncogenes, such as B-RAF (40-60% of cases). Recent studies have shown that vemurafenib (a MAPK inhibitor) promoted disturbance of mitochondrial bioenergetics, although underlying mechanisms are not fully comprehended. Here we showed that MAPK inhibition by vemurafenib in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dynamins
Share to Melanocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitochondrial Dynamics

Share to Mitogen-Activated Protein Kinases

Share to Molecular Targeted Therapy

Share to Oxidative Phosphorylation

Share to Proto-Oncogene Proteins B-raf

Share to Vemurafenib

Source

Identifiers

PMID: 32562785
DOI: 10.1016/j.bcp.2020.114104

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting mitochondria in melanoma: Interplay between MAPK signaling pathway and mitochondrial dynamics.PMID 32562785Read ↗

Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors.Semantic proximity Read ↗

Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review.Semantic proximity Read ↗

Proteogenomic Characterization Reveals Therapeutic Opportunities Related to Mitochondrial Function in MelanomaSemantic proximity Read ↗

Mitochondrial oxidative phosphorylation in cutaneous melanomaSemantic proximity Read ↗

Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.Semantic proximity Read ↗

New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations.Semantic proximity Read ↗

Metabolic rewiring in melanoma drug-resistant cells.Semantic proximity Read ↗

Melanoma Metabolism: Molecular Mechanisms and Therapeutic Implications in Cutaneous OncologySemantic proximity Read ↗

Mitochondrial dysfunction and immune suppression in BRAF V600E-mutated metastatic melanoma.Semantic proximity Read ↗

Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.Semantic proximity Read ↗

Effects of PD-L1 Inhibitors on Mitochondrial Function in Melanoma A375 Cells: Unveiling a Shielded Drug Resistance MechanismSemantic proximity Read ↗

The XBP1-MARCH5-MFN2 Axis Confers ER Stress Resistance by Coordinating Mitochondrial Fission and Mitophagy in MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.